Delcath Systems (DCTHD) Stock Price, News & Analysis

Company Overview

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Key Stats

• Today's Range: $14.82 to $15.81
• 50-Day Range: N/A
• 52-Week Range: $1.22 to $63,000.00
• Volume: 241,245 shs
• Average Volume: 771 shs
• Market Capitalization: $595,200.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DCTHD Stock Analysis - Frequently Asked Questions

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (OTCMKTS:DCTHD) announced its earnings results on Friday, November, 11th. The medical device company reported ($231.00) earnings per share for the quarter, topping analysts' consensus estimates of ($1,151.50) by $920.50. The medical device company had revenue of $0.44 million for the quarter.

When did Delcath Systems' stock split?

Delcath Systems shares reverse split before market open on Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 3rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

Company Calendar

• Last Earnings: 11/11/2016
• Today: 2/22/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Surgical & Medical Instruments
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:DCTHD
• Previous Symbol: NASDAQ:DCTH
• CUSIP: N/A
• CIK: N/A
• Web: www.delcath.com
• Phone: 212-489-2100
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-19,220,000.00
• Net Margins: -1,546.38%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -343.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.53
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $3.41 million
• Price / Sales: 0.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1,036.00) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 40,000
• Free Float: N/A
• Market Cap: $595,200.00
• Optionable: Not Optionable
• Beta: -0.03